



# 利君國際醫藥(控股)有限公司

Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2005)

## APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Wang Xianjun has been appointed as an executive director of the Company with effect from 25 September 2006.

The Board of Directors (the “Board”) of Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”) is pleased to announce that Mr. Wang Xianjun, has been appointed as an executive director of the Company with effect from 25 September 2006. The details of Mr. Wang as required under Rule 13.51(2) of The Rules (the “Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) are set out below.

**Mr. Wang Xian Jun (王憲軍)**, aged 43, is the chief executive officer of the Company and an executive director of Xi'an Lijun Pharmaceutical Company Limited, a wholly-owned subsidiary of the Company (“Xi'an Lijun”). He has over 20 years’ experience in the pharmaceutical industry and is responsible for investor relations and public relations affairs of the Group. Mr. Wang joined Shijiazhuang Pharmaceutical Group in 1987 and became the deputy chief engineer in 1989 and a director in 1993. Mr. Wang was the executive director and vice-chairman of China Pharmaceutical Group Limited, a company whose shares are listed on the Main Board of the Stock Exchange, until December 2002. Mr. Wang was also an independent non-executive director of Greater China Holding Limited, a company whose shares are listed on the Main Board of the Stock Exchange from July 2002 to August 2005. Mr. Wang graduated from Beijing Chemical Engineering College with a Master’s degree in Engineering in 1987. He joined the Group in July 2004 and was the deputy general manager of Xi'an Lijun from July 2004 to December 2004. He was appointed as general manager of the Company in December 2004. Mr. Wang was promoted to chief executive officer of the Company in October 2005 and an executive director of Xi'an Lijun in June 2006.

Save as aforesaid, Mr. Wang does not hold any other positions with the Company and other members of the Group or held any other directorships in listed public companies in the last three years.

Mr. Wang has entered into a service contract with the Company for a fixed term of three years commencing from 25 September 2006, subject to retirement and re-election provisions as set out in the Company’s articles of association. Pursuant to the service contract, the annual director’s emoluments of Mr. Wang is HK\$650,000 together with discretionary bonus based on the Company’s performance. The terms of appointment were approved by the Remuneration Committee of the Company and the Board with reference to Mr. Wang’s qualification, experience and responsibilities to be undertaken. In addition, Mr. Wang is eligible to participate in the Company’s share option scheme. Mr. Wang does not have any relationships with any other directors, senior management or substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

As at the date of this announcement, Mr. Wang was not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 16 February 2000, the Stock Exchange issued a public criticism against certain individuals including Mr. Wang who was a director of China Pharmaceutical Enterprise and Investment Corporation Limited from March 1994 to December 2002, for breaches of Rule 3.08(f) of the Listing Rules and the Director's Declaration and Undertakings in the form set out in Appendix 5B to the Listing Rules in respect of certain connected transactions of China Pharmaceutical Enterprise and Investment Corporation Limited in the period between 1 January 1998 and 7 April 1999.

Save as disclosed above, there is no information which is discloseable nor is/was Mr. Wang involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules; and there are no other matters that need to be brought to the attention of the shareholders of the Company in relation to the appointment of Mr. Wang as an executive director of Company.

The Board would like to express its warm welcome to Mr. Wang on his joining the Board.

On behalf of the Board  
**Wu Qin**  
*Chairman*

Hong Kong, 25 September 2006

*As at the date of this announcement, the Board comprises Wu Qin, Wu Zhihong, Huang Chao, Xie Yunfeng, Sun Xinglai and Wang Xianjun as executive Directors, Liu Zhiyong as non-executive Director and Qu Jiguang, Leung Chong Shun and Chow Kwok Wai as independent non-executive Directors.*